PETER J GRAHAM Insider Trading $ATRS ANTARES PHARMA, INC.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for PETER J GRAHAM.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of PETER J GRAHAM. PETER J GRAHAM is SVP - Chief Legal Officer in E-Z-EM, Inc. ($EZM) and VP - General Counsel in E-Z-EM, Inc. ($EZM) and EVP General Counsel, Secretary in ANTARES PHARMA, INC. ($ATRS) and SVP General Counsel, Secretary in ANTARES PHARMA, INC. ($ATRS).
PETER J GRAHAM in ANTARES PHARMA, INC.
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of PETER J GRAHAM: EVP General Counsel, Secretary, SVP General Counsel, Secretary
Holdings: 582,490 shares
Current Value: $1,281,478
Latest Transaction: Feb 19 2021
$ATRS Market Capitalization: $356.70M
$ATRS Previous Close: $2.20
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of PETER J GRAHAM in ANTARES PHARMA, INC.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Option Exercise | M | 1.12 | 45,000 | 50,400 | 0 | |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Sell | S | 5.05 | 5,000 | 25,250 | 540,417 | 545.4 K to 540.4 K (-0.92 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Sell | S | 4.91 | 40,000 | 196,400 | 545,417 | 585.4 K to 545.4 K (-6.83 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Buy | M | 1.12 | 45,000 | 50,400 | 585,417 | 540.4 K to 585.4 K (+8.33 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 4.73 | 42,073 | 199,005 | 540,417 | 582.5 K to 540.4 K (-7.22 %) |
| Feb 19 2021 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 0.00 | 80,365 | 0 | 582,490 | 502.1 K to 582.5 K (+16.00 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Option Exercise | A | 2.73 | 254,165 | 693,870 | 254,165 | |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.78 | 15,036 | 41,800 | 502,125 | 517.2 K to 502.1 K (-2.91 %) |
| Jun 15 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 2.73 | 131,868 | 360,000 | 517,161 | 385.3 K to 517.2 K (+34.23 %) |
| Jun 09 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 3.13 | 16,261 | 50,897 | 385,293 | 401.6 K to 385.3 K (-4.05 %) |
| Jun 09 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 3.12 | 17,994 | 56,141 | 401,554 | 419.5 K to 401.6 K (-4.29 %) |
| Feb 21 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 3.53 | 29,947 | 105,713 | 419,548 | 449.5 K to 419.5 K (-6.66 %) |
| Feb 21 2020 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 0.00 | 63,234 | 0 | 449,495 | 386.3 K to 449.5 K (+16.37 %) |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Option Exercise | A | 2.92 | 170,227 | 497,063 | 170,227 | |
| Jun 14 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 2.92 | 84,760 | 247,499 | 386,261 | 301.5 K to 386.3 K (+28.11 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.81 | 11,678 | 32,815 | 301,501 | 313.2 K to 301.5 K (-3.73 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.81 | 11,678 | 32,815 | 301,501 | 313.2 K to 301.5 K (-3.73 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.81 | 12,922 | 36,311 | 313,179 | 326.1 K to 313.2 K (-3.96 %) |
| Jun 11 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.81 | 12,922 | 36,311 | 313,179 | 326.1 K to 313.2 K (-3.96 %) |
| Jun 04 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.79 | 15,421 | 43,025 | 326,101 | 341.5 K to 326.1 K (-4.52 %) |
| Feb 22 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 3.20 | 32,386 | 103,635 | 341,522 | 373.9 K to 341.5 K (-8.66 %) |
| Feb 22 2019 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 0.00 | 84,735 | 0 | 373,908 | 289.2 K to 373.9 K (+29.30 %) |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Option Exercise | A | 2.70 | 177,453 | 479,123 | 177,453 | |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Grant | A | 2.70 | 91,667 | 247,501 | 289,173 | 197.5 K to 289.2 K (+46.41 %) |
| Jun 11 2018 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.70 | 12,923 | 34,892 | 197,506 | 210.4 K to 197.5 K (-6.14 %) |
| Jun 05 2018 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | EVP General Counsel ... | Payment of Exercise | F | 2.69 | 15,422 | 41,485 | 210,429 | 225.9 K to 210.4 K (-6.83 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Option Exercise | A | 2.66 | 217,725 | 579,149 | 217,725 | |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Grant | A | 2.66 | 101,434 | 269,814 | 225,851 | 124.4 K to 225.9 K (+81.53 %) |
| Jun 09 2017 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Payment of Exercise | F | 2.57 | 16,633 | 42,747 | 124,417 | 141.1 K to 124.4 K (-11.79 %) |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Option Exercise | A | 1.12 | 257,900 | 288,848 | 257,900 | |
| Jun 06 2016 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Grant | A | 1.12 | 121,050 | 135,576 | 141,050 | 20 K to 141.1 K (+605.25 %) |
| Mar 23 2016 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Buy | P | 0.77 | 20,000 | 15,400 | 20,000 | 0 to 20 K |
| Jul 16 2015 | ATRS | ANTARES PHARMA, IN ... | GRAHAM PETER J | SVP General Counsel ... | Option Exercise | A | 2.29 | 125,000 | 286,250 | 125,000 |
Page: 1